Background {#Sec1}
==========

The use of complementary and alternative medicine (CAM) is expanding throughout the world \[[@CR1], [@CR2]\]. According to the World Health Organization (W.H.O.), CAM includes Ayurveda, traditional Chinese medicine (TCM) and Unani medicine. TCM is widely used in East Asia \[[@CR3]\]. Of the twenty-three million people in Taiwan, 29.1 % used TCM to treat disease in 2014, whereas up to three-fourths of South Korean adults utilized TCM to treat a specific disease \[[@CR4]\].

Hepatitis C virus (HCV), which affects 180 million people globally, is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma \[[@CR5]\]. Conventional anti-viral therapy consisting of pegylated interferon and ribavirin is associated with many intolerable side effects and low response rates in some patients' genotypes \[[@CR6]\]. Therefore, patients often seek for alternative treatments to promote healing and obtain support \[[@CR7]\]. However, the communication regarding CAM between patients and physicians is relatively poor \[[@CR8], [@CR9]\], and the non-disclosure rate is higher than 70 %. Many physicians feel uncomfortable discussing CAM because of their limited knowledge of the subject. Patients avoid discussing CAM with their doctors because they fear receiving a negative response \[[@CR10]\]. To provide holistic care to patients with hepatitis C (HC), physicians should understand the approaches used by patients for symptom relief and health maintenance. In the United States, 80 % of patients with HC used CAM according to a report from 2007 \[[@CR11]\]. Compared with patients with fatty liver disease, patients with HC were approximately 3 times more likely to use CAM \[[@CR12]\]. Because there has been growing interest in using CAM to treat populations with HC worldwide \[[@CR13]\], information about CAM and comprehensive studies on its prevalence, usage patterns, efficacy and safety are important.

TCM, defined by the National Centre for Complementary and Integrative Health (NCCIH, U.S.A.) as an entire medical system of CAM, is a well-established medical system that has been used for more than 2,000 years. TCM is commonly used by the Chinese population, as well as by those in many other countries \[[@CR14]\], including Taiwan \[[@CR15]\]. In Taiwan, TCM has been reimbursed by the National Health Insurance (NHI) programme since 1996. As of 2014, 99.9 % of Taiwan's population were enrolled in the NHI. All of the claims data have been collected in the National Health Insurance Research Database (NHIRD). According to the NHI programme guidelines, TCMs are only provided for outpatient care including Chinese herbal prescriptions, acupuncture, and traumatology manipulative therapy. The utilization prevalence of TCM in Taiwan ranges from 19.8 % to 77.9 % for many diseases including colon cancer \[[@CR16]\], liver cancer \[[@CR17]\], osteoporosis \[[@CR18]\], and type II diabetes mellitus \[[@CR19]\]. However, the utilization and prescription patterns of TCM in HC are lacking.

To characterize the utilization patterns and trends in TCM usage among patients with HC, we analysed a cohort of one million randomly sampled beneficiaries from the NHIRD in 2010. The results of this study should provide valuable information for physicians and for patients with HC.

Methods {#Sec2}
=======

Data source {#Sec3}
-----------

As previously described in detail \[[@CR20]\], all TCM services covered under the NHI are provided only in ambulatory clinics. In Taiwan, TCM physicians (those who have received a series of training in Chinese or both Chinese and Western medicine, all of whom must pass national licensing examinations and complete residency training programmes in hospitals) are requested to make diagnoses based on the International Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) coding \[[@CR16]\]. This study chose one cohort for the analysis, which included one million patients randomly sampled from the beneficiaries of the NHI programme in 2010. The NHIRD contains information on the medical care facilities, physician specialties, and patients' gender, dates of birth, dates of visit, masked identification numbers, prescriptions, management and diagnosis codes in the ICD-9-CM. A maximum of three diagnostic codes were listed in the NHIRD, and all the diagnoses were analysed in our study. This study was approved by the Research Ethics Committee of the Taipei City Hospital (TCHIRB-10406112-E).

Study subjects {#Sec4}
--------------

The study subjects were selected from a random sample of one million individuals in 2010 in the following manner (Fig. [1](#Fig1){ref-type="fig"}): People who had at least three outpatient or inpatient records and had been diagnosed with HCV from January 1, 2000, to December 31, 2010, were defined as patients with HC (ICD-9-CM codes 07054, 0707, 07041, 07044, 07051, V0262). Based on this criteria, there were 8,567 patients older than 18 years old with a new HCV infection diagnosed starting from the index date of January 1, 2000. Patients with HC who had at least one TCM clinical record from 2000 to 2010 were defined as TCM users (*N* = 5,691), whereas those who had no TCM records during the same period were defined as non-TCM users (*N* = 2,876). All study subjects were followed until December 31, 2011.Fig. 1Flow chart of subjects in the one million randomly selected sample from the National Health Insurance Research Database (NHIRD) from 2000 to 2010 in Taiwan

Statistical analysis {#Sec5}
--------------------

The data were analysed using SAS software program, version 9.4 (SAS Institute Inc., Cary, NC, U.S.A.). A univariate analysis was used to compare the TCM users with the non-TCM users. Chi-squared test was performed to assess the relationships between the categorical variables and to examine the differences between TCM users and non-users. Person-years for the follow-up period were calculated for each patient until diagnosis of multisite diseases, censor or December 31, 2011. The person-years and overlapping confidence interval (CI) were calculated to assess incidence density rates. To compare the study cohort to the comparison cohort rate, ratios were examined using a Poisson regression model. Moreover, we estimated the adjusted hazard ratios using Cox proportional hazards model. A *P* value \<0.05 was considered statistically significant.

Results {#Sec6}
=======

Demographic characteristics of the TCM users with HC {#Sec7}
----------------------------------------------------

Of the patients with HC, 66.4 % (*N* = 5,691) had previously used TCM (Table [1](#Tab1){ref-type="table"}). In the TCM users, 54.1 % were female, and this differed from the percentage in non-TCM users, which was only 39.9 %. In both TCM users and non-users, the highest proportion of patients was in the age group from 40 to 64 years old. Regarding the comorbidities of patients with HC, the incidence of most diseases, including osteoarthritis, sicca syndrome, thyroid disorders, chronic obstructive pulmonary disease, and hepatitis B, were higher in TCM users, except for diabetes mellitus, which had a similar incidence in both groups. In contrast, the incidence of hepatocellular carcinoma, liver cirrhosis, and alcohol-related diseases were higher in non-TCM users.Table 1Demographic characteristics of the patients with hepatitis C in Taiwan in 2000-2011VariableNon-TCMTCM*p* value*N* = 2876 (33.57 %)*N* = 5691 (66.43 %)*n*%*n*%Sex\<0.0001 Female114839.92308154.14 Male172860.08261045.86Age at baseline\<0.0001 18−3936412.6694516.61 40−64145150.45339559.66  ≥ 65106136.89135123.74 Mean (STD)58.3414.8553.9213.97Urbanization^a^\<0.0001 1 (highest)57419.96121521.35 273125.42165229.03 344715.5493916.50 4+ (lowest)112439.08188533.12Co-morbidity Hepatitis B57019.82135623.83\<0.0001 Liver cirrhosis98934.39161828.43\<0.0001 hepatocellular carcinoma53518.6089815.780.0009 Alcohol-related disease29410.224778.380.0049 Chronic obstructive pulmonary disease50817.66140224.64\<0.0001 Diabetes Mellitus104636.37214337.660.2449 Thyroid disorders1455.0463111.09\<0.0001 Rheumatoid arthritis893.094007.03\<0.0001 Osteoarthritis95333.14292251.34\<0.0001 Depression1746.0565011.42\<0.0001 Sicca syndrome782.714237.43\<0.0001Charlson comorbidity index score\<0.0001 0120341.83302453.14 137713.1176913.51 More than 2129645.06189833.35Anti-viral or hepatoprotective agents Interferon alfa39213.6397417.11\<0.0001 Ribavirin39113.6097317.10\<0.0001 Silymarin191666.62420473.87\<0.0001Times of visits (mean, SD)15.6117.1821.2323.18\<0.0001^a^The townships within which subjects registered for insurance were grouped into 4 levels of urbanization, based on a score calculated by incorporating variables indicating population density (people/km2), and population ratio of different educational levels, population ratio of elderly, population ratio of people of agriculture workers and the number of physicians per 100,000 people

To examine the frequency of utilization of Western medicine, we analysed the claims data according to the antiviral or hepatoprotective agents used (Table [1](#Tab1){ref-type="table"}). A higher percentage of TCM users than non-TCM users had ever used these agents to control hepatitis C (all *p*-values \< 0.001). TCM users tended to use interferon-alpha, ribavirin, and silymarin to treat HCV (17.1 %, 17.1 %, and 73.9 %, respectively).

With regard to TCM outpatient visits (Table [2](#Tab2){ref-type="table"}), herbal remedies (52.4 %) were the most commonly used therapeutic approach, followed by combined therapy (46.4 %) and acupuncture alone (1.12 %). As for the frequency of visits, the majority of patients visited TCM clinics fewer than three times (74.01 %). Only 16.64 % of the patients visited TCM clinics more than six times.Table 2Distribution of Chinese medicine according to type of Chinese Medicine treatment received in patients with hepatitis C, stratified by number of outpatients visitsNumber of TCM visits (times/per year)Only Chinese herbal remediesOnly Acupuncture or traumatologyCombination both treatmentTotal of TCM (*N* = 5691)*N* = 2984 (52.43 %)*N* = 64 (1.12 %)*N* = 2643 (46.44 %)1-32423 (81.20 %)64 (100 %)1725 (65.27 %)4212 (74.01 %)4-6212 (7.10 %)0320 (12.11 %)532 (9.35 %)\>6349 (11.70 %)0598 (22.63 %)947 (16.64 %)

The prevalence of hepatitis B, liver cirrhosis, alcohol-related disease, chronic obstructive pulmonary disease and diabetes mellitus was lower in TCM users than non-TCM users in Taiwanese HC patients {#Sec8}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

After adjusting for the frequency of outpatient and inpatient visits, Charlson comorbidity index score, and type of service used - only herbal medicine, only acupuncture or a combination - we calculated the disease hazard ratio (HR) of TCM users versus non-TCM users to compare the prevalence of comorbidities between them. We found that TCM users tended to have certain comorbidities less frequently than non-TCM users (Table [3](#Tab3){ref-type="table"}). TCM users had a 0.55 times lower HR of having hepatitis B than non-TCM users (95 % confidence interval 0.46 − 0.66). Patients who received TCM treatment also had a lower ratio for liver cirrhosis (HR 0.42, with 95 % CI 0.37 − 0.48) and alcohol-related disease (HR: 0.31 for the 40−64 age group and 0.41 overall). The prevalence of chronic obstructive pulmonary disease was also lower in the TCM users (HR: 0.59 overall). Diabetes mellitus also showed a lower incidence in TCM users than non-TCM users overall and in each age group (HR: 0.48, 0.40, 0.46 and 0.64 for the sample overall and for the \<40, 40--64, and \>60 age groups, respectively). However, after adjusting for times of visit, Charlson comorbidity index score, and type of TCM service used, the hazard ratio of comorbidities such as sicca syndrome, rheumatoid arthritis, depression, and thyroid disorders was less than 1, with no significance.Table 3Incidence rate ratio for common disease between non-TCM and TCM user in different age groupsAge groups (year-old)Non-TCM userTCM userIRR (95 % CI)Adjusted HR^b^Disease (ICD-9-CM)*N* (%)Person-yearsIR^a^*N* (%)Person-yearsIR^a^(95 % CI)Hepatitis B (70.2, 070.3, V02.61) All570(19.82)1308543.561356(23.83)3935034.460.79(0.72−0.87)\*\*\*0.55(0.46−0.66)\*\*\* 18−3988(24.18)190146.3239(25.29)718933.240.72(0.56−0.92)\*\*0.41(0.25−0.69)\*\*\* 40−64327(22.54)692347.23842(24.80)2390035.230.75(0.66−0.85)\*\*\*0.48(0.37−0.6)\*\*\*  ≥ 65155(14.61)426136.37275(20.36)826033.290.92(0.75−1.11)0.82(0.58−1.17)Liver cirrhosis (571.2, 571.5, 571.6, 572.2, 572.3, 572.4, 572.8, 573.0) All989(34.39)1308575.581618(28.43)3935041.120.54(0.50−0.59)\*\*\*0.42(0.37−0.48)\*\*\* 18−3945(12.36)190123.68108(11.43)718915.020.63(0.45−0.90)\*0.43(0.25−0.73)\*\* 40−64489(33.70)692370.63951(28.01)2390039.790.56(0.51−0.63)\*\*\*0.39(0.33−0.46)\*\*\*  ≥ 65455(42.88)4261106.77559(41.38)826067.670.63(0.56−0.72)\*\*\*0.54(0.44−0.66)\*\*\*hepatocellular carcinoma (155) All535(18.60)1308540.89898(15.78)3935022.820.56(0.50−0.62)\*\*\*0.78(0.45−1.36) 18−396(1.65)19013.1633(3.49)71894.591.45(0.61−3.47)1.25(0.12−12.75) 40−64242(16.68)692334.96514(15.14)2390021.510.62(0.53−0.72)\*\*\*0.98(0.43−2.21)  ≥ 65287(27.05)426167.35351(25.98)826042.490.63(0.54−0.74)\*\*\*0.72(0.29−1.75)Alcohol-related disease (291, 303.0, 303.9, 305.0, 571.0, 571.1, 571.3) All294(10.22)1308522.47477(8.38)3935012.120.54(0.47−0.62)\*\*\*0.41(0.32−0.51)\*\*\* 18−3965(17.86)190134.2124(13.12)718917.250.50(0.37−0.68)\*\*\*0.37(0.24−0.58)\*\*\* 40−64185(12.75)692326.72290(8.54)2390012.130.45(0.38−0.55)\*\*\*0.31(0.23−0.42)\*\*\*  ≥ 6544(4.15)426110.3363(4.66)82607.630.74(0.50−1.09)0.61(0.33−1.16)Chronic obstructive pulmonary disease (491, 492) All508(17.66)1308538.821402(24.64)3935035.630.92(0.83−1.12)0.59(0.50−0.70)\*\*\* 18−3927(7.42)190114.21120(12.70)718916.691.18(0.77−1.78)0.94(0.45−1.97) 40−64198(13.65)692328.6786(23.15)2390032.891.15(0.98−1.34)0.67(0.52−0.86)\*\*  ≥ 65283(26.67)426166.41496(36.71)826060.050.90(0.78−1.05)0.69(0.53−0.89)\*\*Diabetes Mellitus (250) All1046(36.37)1308579.942143(37.66)3935054.460.68(0.63−0.73)\*\*\*0.48(0.42−0.55)\*\*\* 18−3955(15.11)190128.94151(15.98)7189210.73(0.53−0.99)\*0.40(0.22−0.71)\*\* 40−64572(39.42)692382.621358(40.00)2390056.820.69(0.62−0.76)\*\*\*0.46(0.38−0.54)\*\*\*  ≥ 65419(39.49)426198.32634(46.93)826076.750.78(0.69−0.88)\*\*\*0.64(0.51−0.8)\*\*\*Thyroid disease (240, 241, 242, 244) All145(5.04)1308511.08631(11.09)3935016.041.44(1.21−1.73)\*\*\*0.90(0.67−1.21) 18−3921(5.77)190111.05105(11.11)718914.61.32(0.83−2.11)1.33(0.54−3.28) 40−6479(5.44)692311.41418(12.31)2390017.491.53(1.21−1.95)\*\*\*0.9(0.6−1.36)  ≥ 6545(4.24)426110.56108(7.99)826013.071.24(0.87−1.75)0.92(0.53−1.58)Rheumatoid arthritis (714) All89(3.09)130856.8400(7.03)3935010.171.49(1.19−1.88)\*\*\*1.18(0.82−1.69) 18−3911(3.02)19015.7942(4.44)71895.841.01(0.52−1.96)0.88(0.28−2.78) 40−6445(3.10)69236.5266(7.84)2390011.131.71(1.25−2.35)\*\*\*1.38(0.81−2.36)  ≥ 6533(3.11)42617.7492(6.81)826011.141.44(0.97−2.14)1.24(0.69−2.22)Osteoarthritis (715) All953(33.14)1308572.832922(51.34)3935074.261.02(0.95−1.10)0.75(0.66−0.86)\*\*\* 18−3946(12.64)190124.2215(22.75)718929.911.24(0.90−1.70)1.2(0.64−2.27) 40−64427(29.43)692361.681777(52.34)2390074.351.21(1.08−1.34)\*\*\*0.85(0.71−1.03)  ≥ 65480(45.24)4261112.64930(68.84)8260112.591.00(0.90−1.12)0.82(0.67−1)Depression (296.2, 296.3, 296.5, 296.6, 305.8, 311, v790, 290.13) All174(6.05)1308513.3650(11.42)3935016.521.24(1.05−1.47)\*0.78(0.61−1.01) 18−3931(8.52)190116.31128(13.54)718917.81.09(0.74−1.62)0.76(0.42−1.38) 40−6486(5.93)692312.42382(11.25)2390015.981.29(1.02−1.63)\*0.73(0.52−1.04)  ≥ 6557(5.37)426113.38140(10.36)826016.951.27(0.93−1.72)0.89(0.54−1.48)Sicca syndrome (370.33, 710.2) All78(2.71)130855.96423(7.43)3935010.751.80(1.42−2.30)\*\*\*1.27(0.86−1.89) 18−394(1.10)19012.142(4.44)71895.842.78(1.00−7.74)- 40−6440(2.76)69235.78266(7.84)2390011.131.93(1.38−2.69)\*\*\*1.14(0.67−1.94)  ≥ 6534(3.20)42617.98115(8.51)826013.921.75(1.19−2.56)\*\*1.71(0.93−3.15)^**a**^ *IR* incidence rate, per 1000 person-years, *IRR* incidence rate ratio\*:\<0.05; \*\*:\<0.01; \*\*\* *p* \< 0.001^**b**^Hazard Ratio adjusted for times of outpatient and inpatient visit, Charlson comorbidity index score and type of service used - only herbal medicine, only acupuncture and combination of them

Frequency distribution of disease categories in TCM versus non-TCM visits {#Sec9}
-------------------------------------------------------------------------

To delineate the frequency distributions of the disease categories (as the reasons for visits) for the TCM and non-TCM visits, we analysed the ICD-9-CM codes from the claims data (Table [4](#Tab4){ref-type="table"}). There was a significant difference in the disease distributions between the TCM and non-TCM users (*P* \< 0.0001). Among all of the visits, infectious diseases (99.68 %), which included viral hepatitis, were the most common reasons that TCM users visited TCM clinics. Digestive system diseases (99.61 %), which included chronic liver disease, were the second most common reason that TCM users visited TCM clinics. Symptoms/signs and ill-defined conditions (97.96 %) and respiratory system diseases (97.93 %) accounted for the third and fourth disease categories, respectively, followed by diseases of the musculoskeletal system and connective tissue (93.89 %) and injuries (90.77 %). For non-TCM users, infectious diseases (99.51 %) were the most common reason for visiting Western medical clinics, followed by digestive system diseases (97.25 %) and symptoms/signs and ill-defined conditions (89.33 %). When TCM users required medical services, their utilization patterns were similar to those of non-TCM users.Table 4The distribution of TCM and non-TCM user by major disease categories /diagnosis in patients with hepatitis CDisease (ICD-9-CM)Non-TCM user (*N* = 2876)TCM user (*N* = 5691)*p* value*n*%*n*%Infectious and parasitic disease (001−139)286299.51567399.680.2218Neoplasms (140−239)128944.82312154.84\<0.0001Malignant(140−208)82428.65149126.200.0158Benign (210−229)59720.76215237.81\<0.0001Endocrine, nutritional and metabolic disease and immunity disorder (240−279)186364.78413372.62\<0.0001Blood and blood-forming organs (280−289)84329.31187632.960.0006Mental disorder (290−319)120641.93336059.04\<0.0001Nervous system (320−389)208772.57512089.97\<0.0001Circulatory system (390−459)212373.82441077.490.0002Respiratory system (460−519)254888.60557397.93\<0.0001Digestive system (520−579)279797.25566999.61\<0.0001Genitourinary system (580−629)176061.20448578.81\<0.0001Complications of pregnancy, childbirth and the puerperium (630−676)190.661783.13\<0.0001Skin and subcutaneous tissue (680−709)195868.08483084.87\<0.0001Musculoskeletal system and connective tissue (710−739)209172.71534393.89\<0.0001Congenital anomalies (740−759)1264.385118.98\<0.0001Certain conditions originating in the perinatal period (760−779)130.45430.760.0997Symptoms, signs and ill-defined conditions (780−799)256989.33557597.96\<0.0001Injury and poisoning (800−999)199769.44516690.77\<0.0001

The most commonly used TCM prescriptions {#Sec10}
----------------------------------------

To comprehensively understand the TCM prescriptions, including the formulas and herbs, we analysed the claims data, and the results are shown in Table [5](#Tab5){ref-type="table"}. Of the 10 most common formulas of TCM used by patients with HC, Jia-wei-xiao-yao-san (88,124 person-days) was the most commonly used. Xiao-chai-hu-tang (39,837 person-days) and Long-dan-xie-gan-tang (36,293 person-days) accounted for the second and third most commonly used formulas, respectively. With regard to the single herbs used for TCM by patients with HC, Dan-shen (59,252 person-days) was the most common. Yan-hu-suo (41,875 person-days) and Huang-qin (35,273 person-days) were the second and third most commonly used herbs, respectively.Table 5Most common Chinese herbs and formula prescribed for patients with hepatitis CPrescription name (in Chinese)IngredientsTherapeutic action and IndicationNumber of person-daysAverage daily dose (g)Average duration for prescription (days)Single herbDan-shen*Salvia miltiorrhiza* BungeH & E: Activate blood and resolve stasis\
anti-fibrosis, antihepatocarcinoma, anti-diabetic, lipid-lowering592522.510.1Yan-hu-suo*Corydalis yanhusuo*H & E: Activate blood, promote flow of qi, and alleviate pain\
Also used in peptic ulcer4187537.1Huang-qin*Scutellaria baicalensis* GeorgiH: Clear heat and drain fire\
Anti-inflammation352732.28.1Yin-chen-hao*Artemisia capillaris* ThunbH: Excrete dampness and alleviate jaundice\
Anti-fibrosis333572.410.1Da-huang*Rheum officinale* BaillE: Clear heat and drain fire\
Anti-tumor321101.17.9Huang-qi*Astragalus membranaceus*H&E: Qi-tonifying/ restore energy\
Anti-cancer300862.18.8Bei-mu*Fritillariae thunbergii* BulbusE: Clear heat and resolve phlegm\
Also used in peptic ulcer and asthma294042.77.1Ge-gen*Pueraria thomsonii* BenthE: Release exterior and cure heat\
Also used in ischemic heart disease2914327.4Ye-jiao-teng*Polygonum multiflorum* Thunb.E: Nourish heart and induce tranquilization\
Also used in menopausal syndrome285593.38.7Hai-piao-xiao*Sepiella maindronide* RochebruneE: Restrain acidity and alleviate pain279402.58.4FormulaeAlso used in peptic ulcerJia-wei-xiao-yao-san*Glycyrrhiza uralensis* Fisch. *Angelica sinensis*, *Atractylodes macrocephala*, *Bupleurum chinense*, *Gardenia jasminoides*, *Mentha haplocalyx*, *Paeonia lactiflora*, *Paeonia suffruticosa*, *Poria cocos*, *Zingiber officinale*H & E: Harmonize liver and release spleen;\
Also used in thyroid disorders881247.59.3Xiao-chai-hu-tang*Bupleurum chinense*, *Scutellaria baicalensis* Georgi, *Pinellia ternata* (Thunb.) Makino, *Panax ginseng* C.A. Mey, *Glycyrrhiza uralensis* Fisch, *Zingiber officinale*, *Zizyphus jujuba*H: Regulate exterior and interior Qi activity by balancing between yin and yang;\
Antihepatocarcinoma398376.77.9Long-dan-xie-gan-tang*Gentiana scabra* Bge, *Scutellaria baicalensis* Georgi, *Gardenia jasminoides* Ellis, *Alisma orientalis*, *Akebia quinata* (Houtt.) Decne., *Plantago asiatica* L., *Angelica sinensis*, *Rehmannia glutinosa* (Gaert.) Libosch., *Bupleurum chinense*, *Glycyrrhiza uralensis* Fisch.H: Purge fire in the liver and gallbladder, clear away damp-heat in the lower burner;\
Antiinflammation3629311.37.9Shu-jing-huo-xue-tang*Angelica sinensis*, *Paeonia lactiflora* Pall, *Glycyrrhiza uralensis* Fisch, *Rehmannia glutinosa* (Gaert.) Libosch, *Atractylodes lancea*, *Achyranthes bidentata* Blume, *Citrus tangerina pericarpium, Citrus reticulata* Blanco, *Prunus persica* (L.) Batsch, *Clematis chinensis* Osbeck, *Ligusticum striatum* DC., *Stephania tetrandra* S. Moore, *Notopterygium incisum*, *Angelica dahurica* (Fisch. ex Hoffm.) Benth, *Gentiana scabra* Bge, *Poria cocos*, *Zingiber officinale* Rosc.,E: Relax the channels and activate blood;\
Also used in osteoarthritis and rheumatoid arthritis3264610.36.9Xiang-sha-liu-jun-zi-tang*Aquilaria sinensis*, *Amomum villosum* Lour, *Citrus reticulata* Blanco, *Pinellia ternata* (Thunb.), *Panax ginseng* C.A. Mey, *Poria cocos*, *Atractylodes macrocephala* Koidz., *Glycyrrhiza uralensis* Fisch.E: Tonify and replenish qi\
Also used in functional dyspepsia and post-surgery colon cancer patients283817.18.3Gan-lu-yin*Rehmannia glutinosa*, *Asparagus cochinchinensis* (Lour.) Merr., *Liriope spicata* (Thunb.) Lour., *Dendrobium nobile* Lindl., *Artemisia capillaris* Thunb, *Scutellaria baicalensis* Georgi, *Citrus aurantium* L., *Eriobotrya japonica* (Thunb.) Lindl., *Glycyrrhiza uralensis* Fisch,H& E: Clear heat and nourish yin;\
Also used in Sicca syndrome275636.17.6Xue-fu-zhu-yu-tang*Angelica sinensis* (Oliv.) Diels, *Ligusticum chuanxiong* hort, *Paeonia anomala* L., *Prunus persica* (L.), Batsch, *Carthamus tinctorius* L., *Rehmannia glutinosa* (Gaert.) Libosch, *Citrus aurantium* L., *Bupleurum chinense* DC., *Glycyrrhiza uralensis* Fisch, *Platycodon grandiflorum* (Jacq.) A. DC., *Achyranthes bidentata* Blume,E: Promote blood circulation to remove blood stasis\
Also used in ischemic heart disease and hyperlipidemia.274936.68.1Du-huo-ji-sheng-tang*Angelica pubescens* Maxim, *Taxillus chinensis* (DC.) Danser, *Eucommia ulmoides* Oliver, *Achyranthes bidentata* Blume, *Asarum heterotropoides* F. Schmidt, *Gentiana macrophylla* Pall, *Poria cocos*, *Cinnamomum cassia* Presl, *Saposhnikovia divaricata* (Turcz.) Schischk, *Ligusticum striatum* DC., *Panax ginseng* C.A. Mey., *Glycyrrhiza uralensis* Fisch, *Angelica sinensis*, *Paeonia lactiflora* Pall.E: Reinforce the liver and kidney and tonify qi and blood;\
Also used in fracture, osteoarthritis and rheumatoid arthritis2738811.18.2Suan- zao-ren-tang*Ligusticum striatum* DC., *Ziziphus jujuba* Mill. *Poria cocos*, *Glycyrrhiza uralensis* Fisch, *Anemarrhena asphodeloides* BgeE: Nourish blood to tranquilize the mind;\
Also used in insomnia and depression2641787.5Ping-wei-san*Citrus reticulata* Blanco, *Atractylodes lancea* (Thunb.), *Magnolia officinalis* Rehd, *Glycyrrhiza uralensis* FischE: Activate the flow of Qi and regulate the stomach\
Also used in leukemia patients260837.27.6Note: *H* hepatic action, *E* extrahepatic action

Discussion {#Sec11}
==========

This research is the first large-scale study on the utilization patterns of TCM by patients with HC and was conducted by analysing claims data from TCM and non-TCM clinic visits covered by the NHI in Taiwan. In a previous study \[[@CR21]\], Chen et al. investigated the frequency and prescription patterns of Chinese herbal medicine for chronic hepatitis, including viral hepatitis and alcoholic hepatitis, and revealed the same three most common herbal formulas as in our study and a similar age group of patients, approximately in their 40s to 50s, seeking TCM. However, this study focused only on hepatitis C and demonstrated a different gender predominance and more details on comorbidities. According to Sievert's review \[[@CR22]\], the prevalence rate of hepatitis C is as high as 4 %, but the diagnosis rate is only 1.3 %, which is similar to our report. This discrepancy may be due to the fact that only symptomatic patients with HC would visit the hospital and have diagnostic records. Other HCV carriers without medical seeking behaviour would not be recorded in the national health insurance database.

Of the patients with HC, 66.4 % had previously used TCM. The acceptance of TCM among patients with HC is much greater in Taiwan than in other countries \[[@CR11], [@CR12]\]. In addition, approximately 16 % of the patients visited TCM clinics more than six times per year (Table [2](#Tab2){ref-type="table"}). This high visiting frequency might be explained by the fact that many of these patients had chronic illnesses that required long-term care and treatment. Moreover, unlike the predisposition towards acupuncture in Europe \[[@CR23]\], herbal remedies have been widely used in Taiwanese patients with HC (52.4 %). People in Taiwan believe that TCM can adjust the constitution of the human body, allowing small doses of herbal remedies to remain safe and suitable for long-term use \[[@CR24]\]. Furthermore, the insurance coverage for TCM treatments might play a significant role in the high TCM usage in Taiwan \[[@CR25]\]. As for receiving the current standard treatment, the rate of treatment in both arms was low (14 % and 17 %) in our study. This result is consistent with a previous nationwide survey in Taiwan (13.7 %) \[[@CR26]\]. Although the anticipated treatment success rate is as high as 80 % in Taiwan, only 8.1 % of the population with HC achieved successful treatment. The major treatment barriers included fear of adverse effects, major disorders, ineligibility for insurance reimbursement, and lack of awareness of therapy.

Comparing the hazard ratio of comorbidities between TCM users and non-TCM users, the TCM users tended to have a lower risk (0.4 − 0.6 times) of hepatic diseases, suggesting a negative association of hepatitis B, liver cirrhosis, and alcoholic liver disease with TCM usage. One possible explanation for this finding is that the use of TCM might have a protective effect on liver diseases. Another explanation is that patients with impaired liver function would avoid herbal medications to prevent disease progression. The causal relationship warrants further research in the future. However, thyroid diseases, rheumatoid arthritis, osteoarthritis, and sicca syndrome were extrahepatic syndromes that had higher incidence rates in TCM users in Taiwan (Table [4](#Tab4){ref-type="table"}). After adjusting for time of visit, Charlson comorbidity index score, and type of TCM service used, the hazard ratio of these comorbidities became less than 1 and was non-significant. This means the TCM-seeking behaviour is associated with extrahepatic diseases rather than hepatitis C. This finding might be attributed to the side effects of interferon-based antiviral therapy and the lack of satisfaction with the current conventional therapies \[[@CR27]\].

To date, the NHIRD has collected diagnosis data via ICD-9-CM codes, which do not classify TCM syndromes or diagnosis. However, TCM prescriptions including formula or herbs are recorded in the NHIRD. By analysing the prescription patterns, we could obtain the possible TCM syndromes and indications for subjects with HC (Table [5](#Tab5){ref-type="table"}). In our database, the most commonly used formulas and single herbs for HC were categorized into hepatic or extrahepatic based on their therapeutic action and clinical indications. Jia-Wei-Xiao-Yao-San, the most commonly used formula, has demonstrated pleiotropic effects in patients with HC, including anti-hepatic fibrosis \[[@CR28]\], anti-hepatic cancer \[[@CR29]\], anti-depressant \[[@CR30], [@CR31]\], and anti-hyperthyroidism effects \[[@CR32]\]. However, it is unclear whether it has antiviral effects on HCV, and future investigations on this subject are warranted. Dan-Shen (*Salvia miltiorrhiza*), the most commonly used single herb, also has multiple hepatoprotective and extrahepatic effects, such as anti-hepatic fibrosis \[[@CR33]\], anti-hepatic cancer \[[@CR34], [@CR35]\], anti-diabetic \[[@CR36]\], and lipid-lowering \[[@CR37]\] effects, but no apparent antiviral effects. Other commonly used prescriptions had similar multi-target effects, which implied that TCM physicians used these prescriptions to prevent disease progression or to relieve relevant extra-hepatic syndromes rather than to eradicate HCV.

The present study had some limitations. First, this study did not include therapies that were not covered by the NHI, such as newly antiviral agents or folk medicines \[[@CR38]\], which were purchased directly from TCM herbal pharmacies. Consequently, the TCM utilization rates might have been underestimated. However, because only licensed TCM physicians can be reimbursed by the NHI system, the quality of the diagnoses and treatments in the NHIRD were ensured. Second, safety data in this retrospective study are lacking, and thus we cannot evaluate the safety of TCM. Third, our study only examined ambulatory visits to TCM or non-TCM clinics. Our results for visits to Western medical clinics, including inpatient services and emergency department visits, basically concurred with a previous study of outpatient visits \[[@CR39]\]. TCM inpatient services, which mostly included hospital-based healthcare for senile populations, were not that popular and therefore only represented a small proportion of the TCM services received by HC patients.

Conclusion {#Sec12}
==========

In summary, we conducted a nationwide, population-based study on the use of TCM in patients with HC based on one randomly selected cohort in 2010 from the NHIRD healthcare claims data in Taiwan. It is that more than 60 % of the TCM users were female and that the utilization of TCM increased with age and peaked in the age group of those 40 − 64 years old. Patients who had more extrahepatic diseases and were taking more antiviral agents tended to visit TCM clinics. Jia-Wei-Xiao-Yao-San and Dan-Shen (*Salvia miltiorrhiza*) were the most commonly used formula and single herb, with 88,124 person-days and 59,252 person-days, respectively. The high prevalence and distinct usage patterns of TCM in the Taiwanese HC population warrant more substantial, high-quality and/or well-designed clinical trials of TCM use.
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